bsm-34028M

## [ Primary Antibody ]

# BIOSS

www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

# ADGRE1 (F4/80) Mouse mAb

- DATASHEET -

Host: Mouse Isotype: IgG
Clonality: Monoclonal CloneNo.: 3D4
GeneID: 13733 SWISS: Q61549

Target: ADGRE1 (F4/80)

**Purification:** affinity purified by Protein G

Concentration: 200ug/ml

**Storage:** 0.01M PBS (pH7.4) with 0.1% BSA, 0.02% Proclin300.

Shipped at 4°C. Store at -20°C for one year. Avoid repeated

freeze/thaw cycles.

**Background:** The epidermal growth factor (EGF)-TM7 family constitutes a group

of class B G-protein coupled receptors, which includes CD97, EMR1 (EGF-like molecule containing mucin-like hormone receptor 1, designated F4/80 in mouse), EMR2, EMR3, FIRE, and ETL (1-3). These family members are characterized by an extended extracellular region with several N-terminal EGF domains, and are predominantly expressed on cells of the immune system (1–3). The EGF-TM7 protein family are encoded by a gene cluster on human chromosome 19p13 (1,3,4). The F4/80 molecule is solely expressed on the surface of macrophages and serves as a marker for mature macrophage tissues, including Kupffer cells in liver, splenic red pulp macrophages, brain microglia, gut lamina propria, and Langerhans cells in the skin (1). F4/80/EMR1 undergoes extensive N-linked glycosylation as well as some O-linked glycosylation (5,6). The function of F4/80/EMR1 is unclear, but it is speculated to be involved in macrophage adhesion events, cell migration, or as a Gprotein coupled signaling component of macrophages.

Applications: WB (1:500-2000)


Reactivity: Human (predicted: Mouse,

Rat)

Predicted MW.: 95 kDa

Subcellular Cell membrane

### VALIDATION IMAGES



Sample: Lane 1: Human HL-60 cell lysates Primary: Anti-ADGRE1 (F4/80) (bsm-34028M) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Mouse IgG at 1/20000 dilution Predicted hand size: 95 kDa Observed band size: 120 kDa

### - SELECTED CITATIONS -

- [IF=18] Zhuoling Tian. et al. Hydrogen bonding-mediated phase-transition gelatin-based bioadhesives to regulate immune microenvironment for diabetic wound healing. BIOACTIVE MATERIALS. 2025 Jan 2:46:434-447. IF; Mouse.
- [IF=16] Chufan Wang. et al. Enhanced Nano-Vaccine Utilizing Biomineralized Virus-like Particles for Efficient Glioblastoma Immunotherapy via the Nose-To-Brain Delivery Pathway. ACS NANO. 2025;19(22):21154–21168 IF; Mouse. 40442950
- [IF=14.593] Jingxin Hou. et al. LIFU-responsive nanomedicine enables acoustic droplet vaporization-induced apoptosis of macrophages for stabilizing vulnerable atherosclerotic plaques. Bioact Mater. 2022 Mar;: IHC; Mouse.

35386311

- [IF=14.7] Sai Zhu. et al. N6-Methyladenosine modification of circDcbld2 in Kupffer cells promotes hepatic fibrosis via targeting miR-144-3p/Et-1 axis. ACTA PHARM SIN B. 2024 Nov;: IF,IHC; Mouse. 10.1016/j.apsb.2024.11.003
- [IF=14.3] Bin Li. et al. The Thyroid Hormone Analog GC-1 Mitigates Acute Lung Injury by Inhibiting M1 Macrophage Polarization. ADV SCI. 2024 Oct;:2401931 IHC; Mouse. 39373388